Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.

Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.

A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (<30% activity)

Inclusion Criteria:

• • P. vivax peripheral parasitaemia (mono-infection)

  • G6PD intermediate or deficient status (G6PD activity 30-<70% or ≤30% of the adjusted male median as determined by the Standard G6PD (SDBioline, ROK))
  • Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours
  • Age ≥18 years
  • Haemoglobin at presentation ≥8g/dl
  • Written informed consent
  • Living in the study area and willing to be followed for six months.

Exclusion Criteria:

• • Danger signs or symptoms of severe malaria

  • Pregnant or lactating females
  • Regular use of drugs with haemolytic potential
  • Known hypersensitivity to any of the study drugs.